Amgen

Yahoo Finance • 26 days ago

Insiders At Amgen Sold US$4.0m In Stock, Alluding To Potential Weakness

The fact that multiple Amgen Inc. (NASDAQ:AMGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyzing insider transactions, it is usually more valuable to kn... Full story

Yahoo Finance • last month

Amgen must face lawsuit claiming it hid $10.7 billion tax bill

NEW YORK (Reuters) - A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders it might owe the Internal Revenue Service $10.7 billion in taxes and penalties. U.S. Distric... Full story

Yahoo Finance • last month

Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best healthcare stocks to buy according to h... Full story

Yahoo Finance • last month

Amgen Inc. (AMGN): An Undervalued Wide Moat Stock to Buy According to Analysts

We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts.In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other undervalued wide moat stocks. The US e... Full story

Yahoo Finance • last month

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab). HORIZ... Full story

Yahoo Finance • last month

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab... Full story

Yahoo Finance • last month

TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE

THOUSAND OAKS, Calif., Sept. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Ey... Full story

Yahoo Finance • last month

Amgen (NASDAQ:AMGN) shareholders have earned a 15% CAGR over the last five years

The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, while the Amgen Inc. (NASDAQ:AMGN) share price is up 73%... Full story

Yahoo Finance • last month

AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE

THOUSAND OAKS, Calif., Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m. PT on Tuesday, Sept. 24, 2024, to discuss new topline clinical data from the rocatinlimab (AMG 4... Full story

Yahoo Finance • 2 months ago

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types THOUSAND OAKS, Calif., Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipe... Full story

Yahoo Finance • 2 months ago

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSA... Full story

Yahoo Finance • 2 months ago

Amgen Inc. (AMGN): Why Do Hedge Funds Recommend This Biotech Stock?

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds.In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other biotech stocks. As we have mentioned i... Full story

Yahoo Finance • 2 months ago

With 79% institutional ownership, Amgen Inc. (NASDAQ:AMGN) is a favorite amongst the big guns

Key Insights Significantly high institutional ownership implies Amgen's stock price is sensitive to their trading actions A total of 25 investors have a majority stake in the company with 49% ownership Ownership research along with analy... Full story

Yahoo Finance • 2 months ago

3 Unstoppable Dividend Stocks to Buy Right Now

Which income investors want to buy stocks with dividends likely to decline and iffy businesses? None. Instead, income investors want practically unstoppable dividend stocks. Three Motley Fool contributors think they've identified healthca... Full story

Yahoo Finance • 3 months ago

Weekly market recap: Here's how S&P 500 sectors performed last week

US stocks concluded the week with a modest rebound, with the S&P 500 index rising by 0.5%, therefore marking the strongest consecutive daily gains of the year. The rebound in stocks helped to offset much of the losses from earlier in the... Full story

Yahoo Finance • 3 months ago

Are Hedge Funds Bullish on Amgen Inc. (AMGN) Now?

We recently compiled a list of the 10 Best GLP-1 and Weight Loss Stocks to Buy Now.In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other GLP-1 and weight loss stocks. According to WHO, mor... Full story

Yahoo Finance • 3 months ago

Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst

Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst On Tuesday, Amgen Inc. (NASDAQ:AMGN) reported second-quarter sales of $8.39 billion, up 20% year over year and beating the consensus of $8.33 billion.... Full story

Yahoo Finance • 3 months ago

Super Micro Computer, Airbnb, Rivian and Lyft fall premarket; Shopify rises

Investing.com -- U.S. stock futures rose Wednesday, continuing to rebound after the tech-led rout at the start of the week. Here are some of the biggest premarket U.S. stock movers today Walt Disney (NYSE:DIS) stock fell 0.1% in volatil... Full story

Yahoo Finance • 3 months ago

Investors in Amgen (NASDAQ:AMGN) have seen splendid returns of 122% over the past five years

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can do a lot better than that by buying good quality businesses for attractive prices. For example, the Amgen Inc. (NASDAQ:AMGN)... Full story

Yahoo Finance • 3 months ago

10 Best Dividend Growth Stocks to Buy and Hold Forever

Dividend growth stocks typically outperform most other asset classes over five- to 10-year periods. I've selected 10 companies with strong dividend growth records that could amplify your portfolio returns over the long term. These blue-ch... Full story